慢性乙型肝炎患者抗病毒治疗前高尔基体蛋白73与细胞因子的相关性

Correlation of GP73 and cytokines before antiviral therapy in patients with chronic hepatitis B

目的研究慢性乙型肝炎患者干扰素治疗前,不同疗效组患者高尔基体蛋白73(GP73)与细胞因子的相关性,并分析GP73在慢性乙型肝炎的作用。方法收集113例慢性乙型肝炎(CHB)患者干扰素α抗病毒治疗前的血清,采用酶联免疫法检测血清中GP73与TNF-α、IFN-γ、IL-2、IL-10和IL-12等细胞因子的水平,采用Pearson法分析血清GP73与细胞因子的相关性。结果干扰素α治疗病毒学应答组患者血清中GP73、IL-2、IL-12、TNF-α和IFN-γ含量均较部分病毒学应答组患者高,差异具有统计学意义(P均<0.05);无应答组患者血清中IL-2、TNF-α和IFN-γ的含量较部分病毒学应答组高,差异具有统计学意义(P均<0.05);与无应答组对比,病毒学应答组患者仅IL-2和IL-10含量较高,差异具有统计学意义(P均<0.05),两组患者其他指标差异无统计学意义。干扰素α治疗病毒学应答组患者中,治疗前血清GP73与TNF-α、IL-2、IL-12均呈正相关(r=0.8045、P<0.001,r=0.5693、P<0.001,r=0.499、P=0.001),而与IL-10、IFN-γ无相关性。干扰素α治疗部分病毒学应答组患者中,治疗前血清GP73仅与IL-12呈正相关(r=0.4248、P=0.0107),与其他细胞因子无相关性。干扰素α治疗无应答组患者中,治疗前血清GP73与细胞因子均无相关性。此外,病毒学应答组患者血清中GP73、IL-2、IL-12、TNF-α和IFN-γ含量均较部分病毒学应答组高,差异均具有统计学意义(P均<0.05)。结论慢性乙型肝炎患者的血清GP73可能参与免疫调节过程。

Objective To investigate the correlation of serum GP73 and cytokines in different therapeutic groups of patients with chronic hepatitis B before treated with interferon, and to analyze the role of GP73 in chronic hepatitis B. Methods Total of 113 patients with CHB were enrolled. Serum levels of GP73, TNF-α, IFN-γ, IL-2, IL-10 and IL-12 were detected by enzyme-linked immunosorbent assay before patients treated with IFN-α antiviral therapy. The correlations between serum GP73 and cytokines were analyzed by Pearson’s correlations method. Results The concentrations of serum GP73, IL-2, IL-12, TNF-α and IFN-γ in patients with complete response to IFN treatment were signifcantly higher than those in patients with partial response （all P 〈 0.05）. The concentrations of serum IL-2, TNF-α and IFN-γ in patients with non-response to IFN treatment were also signifcantly higher than those in patients with partial response （all P 〈 0.05）. However, there were no signifcant differences between patients with complete response and non-response except for IL-2 and IL-10 （P 〉 0.05）. Moreover, there were signifcant positive correlationsbetween serum GP73 and cytokines of TNF-α （r = 0.8045, P 〈 0.001）, IL-2 （r = 0.5693, P 〈 0.001） and IL-12 （r = 0.499, P = 0.001） in patients with complete response to IFN treatment. And in patients with partial response, the correlation between serum GP73 and IL-12 （r = 0.4248, P = 0.0107） was signifcant, however, the correlation between serum GP73 and the other cytokines were not signifcant. The level of GP73 andcytokines in patients with non-response to IFN treatment were with no correlation. Conclusions GP73 in patients with CHB may participate in immune regulation.